FDLI Off-Label Promotion Discussion Ventures Into “Abstract” Territory
This article was originally published in The Gray Sheet
Executive Summary
Companies should request records of FDA correspondence related to premarket notification when weighing the purchase of another firm's 510(k), attorney Jeffrey Gibbs advised during a Sept. 13-14 Food & Drug Law Institute meeting in Washington, D.C
You may also be interested in...
FDA Denies WLF Petition To Allow Dissemination Of Off-Label Information
Dissemination of journal reprints representing off-label use of a device or drug will not by themselves trigger FDA enforcement action against a manufacturer, according to the agency
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.